메뉴 건너뛰기




Volumn 17, Issue 6, 2011, Pages 906-913

Efficacy of anthiyperglycemic therapies and the influence of baseline hemoglobin A1C: A meta-analysis of the liraglutide development program

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE RECEPTOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

EID: 84855829644     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP.17.6.906     Document Type: Article
Times cited : (44)

References (19)
  • 1
    • 33845340507 scopus 로고    scopus 로고
    • Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: A meta-regression analysis
    • DOI 10.2337/dc06-1120
    • Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering effcacy: a meta-regression analysis. Diabetes Care. 2006;29:2137-2139. (Pubitemid 44871202)
    • (2006) Diabetes Care , vol.29 , Issue.9 , pp. 2137-2139
    • Bloomgarden, Z.T.1    Dodis, R.2    Viscoli, C.M.3    Holmboe, E.S.4    Inzucchi, S.E.5
  • 2
    • 77949416255 scopus 로고    scopus 로고
    • Relationship of baseline HbA1c and effcacy of current glucose-lowering therapies: A meta-analysis of randomized clinical trials
    • DeFronzo RA, Stonehouse AH, Han J, Wintle ME. Relationship of baseline HbA1c and effcacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med. 2010;27:309-317.
    • (2010) Diabet Med. , vol.27 , pp. 309-317
    • Defronzo, R.A.1    Stonehouse, A.H.2    Han, J.3    Wintle, M.E.4
  • 3
    • 77958172772 scopus 로고    scopus 로고
    • The effect of oral antidiabetic agents on A1C levels: A systematic review and meta-analysis
    • Sherifali D, Nerenberg K, Pullenayegum E, Cheng JE, Gerstein HC. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care. 2010;33:1859-1864.
    • (2010) Diabetes Care. , vol.33 , pp. 1859-1864
    • Sherifali, D.1    Nerenberg, K.2    Pullenayegum, E.3    Cheng, J.E.4    Gerstein, H.C.5
  • 4
    • 73349102524 scopus 로고    scopus 로고
    • The safety and effcacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: An overview of the LEAD 1-5 studies
    • Blonde L, Russell-Jones D. The safety and effcacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab. 2009;11(suppl 3):26-34.
    • (2009) Diabetes Obes Metab. , vol.11 , Issue.SUPPL. 3 , pp. 26-34
    • Blonde, L.1    Russell-Jones, D.2
  • 5
    • 67649666737 scopus 로고    scopus 로고
    • Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
    • (LEAD-6 Study Group).
    • Buse JB, Rosenstock J, Sesti G, et al (LEAD-6 Study Group). Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39-47.
    • (2009) Lancet. , vol.374 , pp. 39-47
    • Buse, J.B.1    Rosenstock, J.2    Sesti, G.3
  • 6
    • 77952309372 scopus 로고    scopus 로고
    • Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: A 26-week, randomised, parallel-group, open-label trial
    • 1860 -LIRA-DPP-4 Study Group)
    • Pratley RE, Nauck M, Bailey T, et al (1860-LIRA-DPP-4 Study Group). Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375:1447-1456.
    • (2010) Lancet. , vol.375 , pp. 1447-1456
    • Pratley, R.E.1    Nauck, M.2    Bailey, T.3
  • 7
    • 26944477362 scopus 로고    scopus 로고
    • Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial
    • (GWAA Study Group).
    • Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG (GWAA Study Group). Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005; 143:559-569.
    • (2005) Ann Intern Med. , vol.143 , pp. 559-569
    • Heine, R.J.1    Van Gaal, L.F.2    Johns, D.3    Mihm, M.J.4    Widel, M.H.5    Brodows, R.G.6
  • 9
    • 77953951577 scopus 로고    scopus 로고
    • American Association of Clinical Endocrinologists/American College of Endocrinology statement on the use of hemoglobin A1c for the diagnosis of diabetes
    • American Association of Clinical Endocrinologists Board of Directors and American College of Endocrinologists Board of Trustees
    • American Association of Clinical Endocrinologists Board of Directors and American College of Endocrinologists Board of Trustees. American Association of Clinical Endocrinologists/American College of Endocrinology statement on the use of hemoglobin A1c for the diagnosis of diabetes. Endocr Pract. 2010;16:155-156.
    • (2010) Endocr Pract. , vol.16 , pp. 155-156
  • 10
    • 59449101432 scopus 로고    scopus 로고
    • Liraglutide versus glimepiride monother-apy for type 2 diabetes (LEAD-3 Mono): A randomised 52-week phase III double-blind parallel-treatment trial
    • (LEAD-3 [Mono] Study Group)
    • Garber A, Henry R, Ratner R, et al (LEAD-3 [Mono] Study Group). Liraglutide versus glimepiride monother-apy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473-481.
    • (2009) Lancet. , vol.373 , pp. 473-481
    • Garber, A.1    Henry, R.2    Ratner, R.3
  • 11
    • 62449129181 scopus 로고    scopus 로고
    • Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)
    • (LEAD-1 SU Study Group).
    • Marre M, Shaw J, Brändle M, et al (LEAD-1 SU Study Group). Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-278.
    • (2009) Diabet Med , vol.26 , pp. 268-278
    • Marre, M.1    Shaw, J.2    Brändle, M.3
  • 12
    • 62449169287 scopus 로고    scopus 로고
    • Effcacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metfor-min, in type 2 diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
    • (LEAD-2 Study Group).
    • Nauck M, Frid A, Hermansen K, et al (LEAD-2 Study Group). Effcacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metfor-min, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care. 2009;32:84-90.
    • (2009) Diabetes Care. , vol.32 , pp. 84-90
    • Nauck, M.1    Frid, A.2    Hermansen, K.3
  • 13
    • 69949117621 scopus 로고    scopus 로고
    • Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 Met+SU): A randomised controlled trial
    • (Liraglutide Effect and Action in Diabetes 5 [LEAD-5] Met+SU Study Group)
    • Russell-Jones D, Vaag A, Schmitz O, et al (Liraglutide Effect and Action in Diabetes 5 [LEAD-5] Met+SU Study Group). Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 Met+SU): a randomised controlled trial. Diabetologia. 2009;52:2046-2055.
    • (2009) Diabetologia. , vol.52 , pp. 2046-2055
    • Russell-Jones, D.1    Vaag, A.2    Schmitz, O.3
  • 14
    • 67650066860 scopus 로고    scopus 로고
    • Effcacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with met-formin and thiazolidinedione in patients with type 2 dia-betes (LEAD-4 Met+TZD) [published correction appears in Diabetes Care. 2010; 33:692]
    • (LEAD-4 Study Investigators).
    • Zinman B, Gerich J, Buse JB, et al (LEAD-4 Study Investigators). Effcacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with met-formin and thiazolidinedione in patients with type 2 dia-betes (LEAD-4 Met+TZD) [published correction appears in Diabetes Care. 2010;33:692]. Diabetes Care. 2009;32: 1224-1230.
    • (2009) Diabetes Care. , vol.32 , pp. 1224-1230
    • Zinman, B.1    Gerich, J.2    Buse, J.B.3
  • 15
    • 0037569239 scopus 로고    scopus 로고
    • Are the metabolic effects of rosiglitazone influenced by baseline glycaemic control?
    • DOI 10.1185/030079903125001695
    • Goldstein BJ, Cobitz AR, Hand LM, Chen H. Are the metabolic effects of rosiglitazone infuenced by baseline glycaemic control? Curr Med Res Opin. 2003;19:192-199 (Pubitemid 36613002)
    • (2003) Current Medical Research and Opinion , vol.19 , Issue.3 , pp. 192-199
    • Goldstein, B.J.1    Cobitz, A.R.2    Hand, L.M.3    Chen, H.4
  • 16
    • 33751335302 scopus 로고    scopus 로고
    • 1c: A meta-analysis of published randomized clinical trials
    • DOI 10.1185/030079906X148328
    • Phatak HM, Yin DD. Factors associated with the effect-size of thiazolidinedione (TZD) therapy on HbA(1c): a meta-analysis of published randomized clinical trials. Curr Med Res Opin. 2006;22:2267-2278. (Pubitemid 44801495)
    • (2006) Current Medical Research and Opinion , vol.22 , Issue.11 , pp. 2267-2278
    • Phatak, H.M.1    Yin, D.D.2
  • 18
    • 85038456735 scopus 로고    scopus 로고
    • Accessed for verifcation November 7
    • American Association of Clinical Endocrinologists. AACE/ACE diabetes algorithm for glycemic control. https://aace.com/sites/default/files/ GlycemicControl AlgorithmPPT.pdf. Accessed for verifcation November 7, 2011.
    • (2011) AACE/ACE Diabetes Algorithm for Glycemic Control.
  • 19
    • 19944368427 scopus 로고    scopus 로고
    • Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: Comparison of two treatment algorithms using insulin glargine
    • DOI 10.2337/diacare.28.6.1282
    • Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R (AT.LANTUS Study Group). Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005;28:1282-1288. (Pubitemid 40756686)
    • (2005) Diabetes Care , vol.28 , Issue.6 , pp. 1282-1288
    • Davies, M.1    Storms, F.2    Shutler, S.3    Bianchi-Biscay, M.4    Gomis, R.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.